Építés alatt – nem éles oldal

Ugrás a tartalomra

Frontlight Research

Intézmény

Institut Català d'Oncologia

Barcelona, SpanyolországgovernmentHonlap

Más néven: Catalan Institute of Oncology · Instituto Catalán de Oncología · ICO

562futó vizsgálat
211lezárt vizsgálat
0a helyszín által az elmúlt 60 napban megerősített vizsgálat
–nyelv nincs megadva

A helyszín még egy vizsgálatot sem erősített meg.

Futó vizsgálatok

Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· 3. fázis· Forrás
Még nem toboroz
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
2026-525367-40-00· 3. fázis· Forrás
Még nem toboroz
A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma
NCT07192471· 1. fázis· Forrás
Még nem toboroz
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895· 1/2. fázis· Forrás
Még nem toboroz
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
2024-518348-19-00· 1. fázis· Forrás
Még nem toboroz
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
2025-524969-24-00· 3. fázis· Forrás
Még nem toboroz
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2026-526352-31-00· 2. fázis· Forrás
Még nem toboroz
ITR-251 in Patients With Advanced Solid Tumors
NCT07870096· 1. fázis· Forrás
Toboroz
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
2025-525030-57-00· 3. fázis· Forrás
Toboroz
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
2026-525328-10-00· 2. fázis· Forrás
Toboroz
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· 3. fázis· Forrás
Toboroz
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· 1/2. fázis· Forrás
Toboroz
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
NCT07465757· 2. fázis· Forrás
Még nem toboroz
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
NCT07247786· 2. fázis· Forrás
Még nem toboroz
A phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation
2026-525964-17-00· 2. fázis· Forrás
Toboroz
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764· 2. fázis· Forrás
Toboroz
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· 3. fázis· Forrás
Toboroz
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· 3. fázis· Forrás
Toboroz
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
NCT07473128· 3. fázis· Forrás
Toboroz
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
NCT07807163· 2. fázis· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
NCT07564141· 3. fázis· Forrás
Toboroz
A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.
NCT07460986· 1/2. fázis· Forrás
Toboroz
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052· 3. fázis· Forrás
Még nem toboroz
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· 3. fázis· Forrás
Toboroz
Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma
NCT07475572· 1. fázis· Forrás
Toboroz
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· 3. fázis· Forrás
Toboroz
Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
2023-510560-12-00· 2. fázis· Forrás
Toboroz
CLEAR (Cervical Lymphatic Exclusion in Adjuvant Radiation)
NCT07755449· 2. fázis· Forrás
Toboroz
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
2025-523815-12-00· 3. fázis· Forrás
Toboroz
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287· 2. fázis· Forrás
Toboroz
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002· 2/3. fázis· Forrás
Toboroz
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00· 3. fázis· Forrás
Toboroz
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· 3. fázis· Forrás
Toboroz
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
NCT07634471· 2/3. fázis· Forrás
Toboroz
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339· 3. fázis· Forrás
Toboroz
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319· 2/3. fázis· Forrás
Toboroz
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
NCT07154745· 3. fázis· Forrás
Toboroz
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· 3. fázis· Forrás
Toboroz
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
NCT07333066· 3. fázis· Forrás
Toboroz
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· 3. fázis· Forrás
Még nem toboroz
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
NCT07593040· 2. fázis· Forrás
Még nem toboroz
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· 2. fázis· Forrás
Még nem toboroz
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
2025-524014-29-00· 3. fázis· Forrás
Toboroz
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· 3. fázis· Forrás
Toboroz
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· 3. fázis· Forrás
Toboroz
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00· 1. fázis· Forrás
Toboroz
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282· 3. fázis· Forrás
Toboroz
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· 3. fázis· Forrás
Toboroz
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
NCT07570173· 2/3. fázis· Forrás
Toboroz
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Tüdőrák107 toboroz
Petefészekrák37 toboroz
Mielóma multiplex33 toboroz
Áttétes emlőrák27 toboroz
Prosztatarák27 toboroz
Akut mieloid leukémia (AML)24 toboroz
Hasnyálmirigyrák23 toboroz
Vastagbélrák21 toboroz
Fej-nyaki daganatok20 toboroz
Gyermekkori daganatok20 toboroz
Méhtestrák20 toboroz
Gyomor- és nyelőcsőrák19 toboroz
Melanóma14 toboroz
Mielodiszplasztikus szindróma (MDS)14 toboroz
Mieloproliferatív neopláziák12 toboroz
Hodgkin-limfóma11 toboroz
Krónikus limfoid leukémia (CLL)11 toboroz
Tripla negatív emlőrák10 toboroz
Follikuláris limfóma9 toboroz
Hólyagrák9 toboroz
Máj- és epeúti rák9 toboroz
Akut limfoid leukémia (ALL)8 toboroz
Diffúz nagy B-sejtes limfóma (DLBCL)8 toboroz
Vesedaganat8 toboroz
Krónikus mieloid leukémia (CML)7 toboroz
Köpenysejtes limfóma6 toboroz
Méhnyakrák6 toboroz
Szarkóma3 toboroz
Glioblasztóma2 toboroz
Neuroendokrin daganatok2 toboroz
Asztma1 toboroz
Mezotelióma1 toboroz
Pajzsmirigyrák1 toboroz
Sarlósejtes vérszegénység1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

Lezárult
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.
2025-523984-39-00· 2. fázis· Forrás
Lezárult
A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC
2025-522867-13-00· 2. fázis· Forrás
Lezárult
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)
2025-521489-80-00· 2. fázis· Forrás
Toboroz
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· 3. fázis· Forrás
Lezárult
C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT05896163· 1/2. fázis· Forrás
Fut, nem toboroz
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)
2024-517818-15-00· 1/2. fázis· Forrás
Lezárult
A study to learn about the study medicine called PF-08046032 in people with advanced cancers.
2024-517756-35-00· 1. fázis· Forrás
Lezárult
A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status
2024-511239-91-00· 2. fázis· Forrás
Lezárult
A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KRAS-G12D mutation, when given alone and with other cancer drugs
NCT06599502· 1/2. fázis· Forrás
Lezárult
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
NCT06587451· 3. fázis· Forrás
Fut, nem toboroz
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265· 3. fázis· Forrás
Lezárult
Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF-AIO Phase IIa BEMARA trial
NCT06680622· 2. fázis· Forrás
Fut, nem toboroz
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132· 1/2. fázis· Forrás
Fut, nem toboroz
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06604715· 1. fázis· Forrás
Lezárult
A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers
2023-507674-41-00· 1. fázis· Forrás
Lezárult
A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors
2022-502367-37-00· 1/2. fázis· Forrás
Fut, nem toboroz
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042· 3. fázis· Forrás
Lezárult
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· 2. fázis· Forrás
Fut, nem toboroz
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217· 1. fázis· Forrás
Lezárult
A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced lung cancer.
NCT06173505· 1/2. fázis· Forrás
Fut, nem toboroz
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
NCT06359002· 1. fázis· Forrás
Lezárult
A safety study of PF-08046045/SGN-35T in adults with advanced cancers
NCT06120504· 1. fázis· Forrás
Lezárult
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· 3. fázis· Forrás
Lezárult
EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer
NCT05075577· 1/2. fázis· Forrás
Lezárult
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1
NCT05870748· 2. fázis· Forrás
Lezárult
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
2023-506881-30-00· 1. fázis· Forrás
Fut, nem toboroz
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· 3. fázis· Forrás
Lezárult
A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan
NCT05954143· 2. fázis· Forrás
Toboroz
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456· 3. fázis· Forrás
Lezárult
Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.
NCT04777851· 3. fázis· Forrás
Lezárult
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
NCT05109975· 1. fázis· Forrás
Lezárult
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
2023-506092-10-00· 2. fázis· Forrás
Lezárult
Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab treatment in patients with endometrial cancer after disease progression to a previous treatment with Platinum-based Chemotherapy. LiDer trial
2023-508583-30-00· 1/2. fázis· Forrás
Lezárult
A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC
2022-503007-22-00· 2. fázis· Forrás
Lezárult
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)
2023-505910-10-00· 2. fázis· Forrás
Lezárult
Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.
2022-502413-29-00· 2. fázis· Forrás
Lezárult
Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN
2023-505796-76-00· 1. fázis· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· 2. fázis· Forrás
Lezárult
Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors
NCT06024174· 1/2. fázis· Forrás
Lezárult
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma.
NCT04718675· 1. fázis· Forrás
Lezárult
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
NCT05963984· 2. fázis· Forrás
Lezárult
Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer
NCT05724602· 2. fázis· Forrás
Lezárult
A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patients with a mutation in the STK11 gene
NCT05469178· 1/2. fázis· Forrás
Lezárult
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
2022-502057-33-00· 1/2. fázis· Forrás
Lezárult
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT05848011· 2. fázis· Forrás
Lezárult
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
2022-502787-20-00· 2. fázis· Forrás
Fut, nem toboroz
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886· 3. fázis· Forrás
Lezárult
A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours
2023-504376-21-00· 1. fázis· Forrás
Lezárult
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
NCT05909904· 2. fázis· Forrás
Lezárult
Clinical trial of MK-7648A in adults and children with skin cancer
NCT05665595· 3. fázis· Forrás

Vizsgálati helyszínek

Catalan Institute of Oncology13 vizsgálat
Catalan Institute of Oncology Badalona0 vizsgálat
Institut Catala d'Oncologia297 vizsgálat
Institut Català d'Oncologia Badalona3 vizsgálat
Institut Catala d Oncologia Badalona (Site 1201)0 vizsgálat
Institut Català d' Oncologia de Badalona1 vizsgálat
Instituto Catalán de Oncología Badalona1 vizsgálat
Catalan Institute of Oncology2 vizsgálat
Institut Catala d'Oncologia17 vizsgálat
Institut Catala D'oncologia - Oncologia1 vizsgálat
Institut Catala d'Oncologia (Site # 1302)0 vizsgálat
Instituto Catalán de Oncologia0 vizsgálat
Catalan Institute of Oncology2 vizsgálat
Institut Català d'Oncologia138 vizsgálat
Instituto Catalán de Oncología1 vizsgálat
Instituto Catalán de Oncología1 vizsgálat
Catalan Institute of Oncology33 vizsgálat
Institut Catala D'oncologia482 vizsgálat
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology (Site 0501)1 vizsgálat
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology (Site 1603)0 vizsgálat
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology (Site 2305)0 vizsgálat
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology (Site 2401)0 vizsgálat
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology (Site 2406)0 vizsgálat
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology (Site 2508)0 vizsgálat
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology (Site 2901)0 vizsgálat
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology (Site 3608)0 vizsgálat
Instituto Catalán de Oncología1 vizsgálat
INSTITUTO CATALAN DE ONCOLOGÍA - ICO Oncología Médica1 vizsgálat
Instituto Catalan de Oncologia L'Hospitalet1 vizsgálat

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

Mielóma multiplex38 munka · 66 vizsgálat
Petefészekrák32 munka · 51 vizsgálat
Méhtestrák26 munka · 27 vizsgálat
Fej-nyaki daganatok23 munka · 42 vizsgálat
Hodgkin-limfóma20 munka · 32 vizsgálat
Áttétes emlőrák17 munka · 65 vizsgálat
Mielodiszplasztikus szindróma (MDS)12 munka · 23 vizsgálat
Follikuláris limfóma8 munka · 23 vizsgálat
Krónikus limfoid leukémia (CLL)7 munka · 22 vizsgálat
Köpenysejtes limfóma6 munka · 17 vizsgálat
Mezotelióma6 munka · 2 vizsgálat
Mieloproliferatív neopláziák6 munka · 17 vizsgálat

Intézményadatok: ROR 01j1eb875 (CC0-1.0)Frissítve: 2026. nov. 10.